(RTTNews) - AbbVie, Inc. (ABBV), a pharmaceutical company, announced a partnership with Valkai, a life sciences artificial intelligence platform, to enhance its AI infrastructure and accelerate scientific innovation. Through the partnership, AbbVie will deploy purpose-built AI capabilities to improve efficiency across targeted areas of clinical research. The initiative aims to help teams generate insights more quickly and support opportunities to reduce development timelines. AI serves as a critical tool at AbbVie to complement employee insight and enable teams to drive strategic priorities and expedite medicine delivery to patients. The company maintains a strong commitment to responsible and ethical use of the technology.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.